

Karl B Lemstra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/919017/publications.pdf>

Version: 2024-02-01

111
papers

2,602
citations

172457

29
h-index

206112

48
g-index

115
all docs

115
docs citations

115
times ranked

2738
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibition of Vascular Endothelial Growth Factor Receptors 1 and 2 Attenuates Natural Killer Cell and Innate Immune Responses in an Experimental Model for Obliterative Bronchiolitis. <i>American Journal of Pathology</i> , 2022, 192, 254-269.	3.8	3
2	Plasma proteome of brain-dead organ donors predicts heart transplant outcome. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 311-324.	0.6	7
3	Monogenic gene variants in lung transplant recipients with usual interstitial pneumonia. <i>ERJ Open Research</i> , 2022, 8, 00583-2021.	2.6	2
4	Cancer risk and mortality after solid organ transplantation: A population-based 30-year cohort study in Finland. <i>International Journal of Cancer</i> , 2022, 150, 1779-1791.	5.1	24
5	Failing Heart Transplants and Rejection—A Cellular Perspective. <i>Journal of Cardiovascular Development and Disease</i> , 2021, 8, 180.	1.6	3
6	Cholesterol lowering with EVOlocumab to prevent cardiac allograft Vasculopathy in De novo heart transplant recipients: Design of the randomized controlled EVOLVD trial. <i>Clinical Transplantation</i> , 2020, 34, e13984.	1.6	15
7	Cost-utility of venoarterial extracorporeal membrane oxygenation in cardiogenic shock and cardiac arrest. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 333-341.	1.0	14
8	Hypoxia-inducible factor controls immunoregulatory properties of myeloid cells in mouse cardiac allografts - an experimental study. <i>Transplant International</i> , 2019, 32, 95-106.	1.6	9
9	Donor Simvastatin Treatment in Heart Transplantation. <i>Circulation</i> , 2019, 140, 627-640.	1.6	24
10	Extracorporeal membrane oxygenation for refractory cardiogenic shock: patient survival and health-related quality of life. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, 780-787.	1.4	14
11	Platelet-derived Growth Factor-B Protects Rat Cardiac Allografts From Ischemia-reperfusion Injury. <i>Transplantation</i> , 2016, 100, 303-313.	1.0	11
12	Ischemia-Reperfusion Injury Enhances Lymphatic Endothelial VEGFR3 and Rejection in Cardiac Allografts. <i>American Journal of Transplantation</i> , 2016, 16, 1160-1172.	4.7	37
13	Increased myeloid cell hypoxia-inducible factor-1 delays obliterative airway disease in the mouse. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 671-678.	0.6	3
14	Simvastatin Treatment Upregulates Anti-Fibrotic Bone Morphogenetic Protein-7 Expression at Rat Cardiac Allograft Rejection. <i>Pharmacology</i> , 2016, 98, 204-208.	2.2	1
15	<sc>VEGF</sc> Pathways in the Lymphatics of Healthy and Diseased Heart. <i>Microcirculation</i> , 2016, 23, 5-14.	1.8	29
16	Simvastatin pretreatment reduces caspase-9 and RIPK1 protein activity in rat cardiac allograft ischemia-reperfusion. <i>Transplant Immunology</i> , 2016, 37, 40-45.	1.2	17
17	Systemic overexpression of matricellular protein CCN1 exacerbates obliterative bronchiolitis in mouse tracheal allografts. <i>Transplant International</i> , 2015, 28, 1416-1425.	1.6	8
18	Cancer Risk After Heart Transplantation Highly Elevated in Comparison to General Population. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, S303-S304.	0.6	0

#	ARTICLE	IF	CITATIONS
19	PDGF-B Is Protective During Ischemia-Reperfusion Injury in Rat Cardiac Allografts. Journal of Heart and Lung Transplantation, 2015, 34, S267-S268.	0.6	0
20	Lymphatic Endothelial Cell VEGFR3 Controls Cardiac Allograft Rejection. Journal of Heart and Lung Transplantation, 2015, 34, S93.	0.6	0
21	VEGF-B Overexpression Enhances Ischemia-Reperfusion Injury and the Innate Immune Response in Rat Heart Transplants. Journal of Heart and Lung Transplantation, 2015, 34, S264-S265.	0.6	0
22	Donor Heart Treatment With COMP-Ang1 Limits Ischemia-Reperfusion Injury and Rejection of Cardiac Allografts. American Journal of Transplantation, 2015, 15, 2075-2084.	4.7	19
23	Transgenic Overexpression of Cardiac-Specific Vascular Endothelial Growth Factor B Exacerbates Ischemia Reperfusion Injury in Rat Cardiac Grafts.. Transplantation, 2014, 98, 352-353.	1.0	0
24	Donor Single-dose Treatment with VEGFR-3 Antibody Reduces Acute Alloimmune Response by Targeting Lymphatic Endothelial Cell Activation. Journal of Heart and Lung Transplantation, 2014, 33, S165.	0.6	0
25	Long-Term Outcomes of Left Ventricular Assist Device Therapy in Scandinavia. Journal of Heart and Lung Transplantation, 2014, 33, S216.	0.6	0
26	Angiotensin-2 Inhibition Prevents Transplant Ischemia-Reperfusion Injury and Chronic Rejection in Rat Cardiac Allografts. American Journal of Transplantation, 2014, 14, 1096-1108.	4.7	32
27	Combined Short Term Caspofungin and Nebulized Amphotericin B Prophylaxis May Help To Eradicate Aspergillus Related Complications After Lung Transplantation. Journal of Heart and Lung Transplantation, 2014, 33, S180.	0.6	0
28	Ex Vivo Intracoronary Gene Transfer of Adeno Associated Virus Serotype 2 Is Superior to Serotypes 8 and 9 in Transfecting Heart Transplants in the Rat. Journal of Heart and Lung Transplantation, 2013, 32, S250-S251.	0.6	0
29	Three decades of heart transplantation in Scandinavia: long-term follow-up. European Journal of Heart Failure, 2013, 15, 308-315.	7.1	38
30	Ex vivo intracoronary gene transfer of adeno-associated virus 2 leads to superior transduction over serotypes 8 and 9 in rat heart transplants. Transplant International, 2013, 26, 1126-1137.	1.6	8
31	Donor simvastatin treatment and cardiac allograft ischemia/reperfusion injury. Trends in Cardiovascular Medicine, 2013, 23, 85-90.	4.9	9
32	VEGF Receptor Signaling in the Cardiac Lymphatics. , 2013, , 125-143.		1
33	Donor Simvastatin Treatment Prevents Ischemia-Reperfusion and Acute Kidney Injury by Preserving Microvascular Barrier Function. American Journal of Transplantation, 2013, 13, 2019-2034.	4.7	41
34	Differential Effects of Pharmacological HIF Preconditioning of Donors Versus Recipients in Rat Cardiac Allografts. American Journal of Transplantation, 2013, 13, 600-610.	4.7	16
35	Combined Donor Simvastatin and Methylprednisolone Treatment Prevents Ischemia-Reperfusion Injury in Rat Cardiac Allografts Through Vasculoprotection and Immunomodulation. Transplantation, 2013, 95, 1084-1091.	1.0	10
36	Effect of simvastatin on development of obliterative airway disease: An experimental study. Journal of Heart and Lung Transplantation, 2012, 31, 194-203.	0.6	8

#	ARTICLE	IF	CITATIONS
37	354 Blocking VEGF Receptors 1 and 2 Prevents Inflammatory Response and Experimental Obliterative Airway Disease. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, S126.	0.6	0
38	498 Combined Prophylactic and Pre-Emptive CMV Strategy with Valganciclovir in Heart Transplant Patients Is Efficacious and Safe. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, S174-S175.	0.6	0
39	Critical Role of VEGF-C/VEGFR-3 Signaling in Innate and Adaptive Immune Responses in Experimental Obliterative Bronchiolitis. <i>American Journal of Pathology</i> , 2012, 181, 1607-1620.	3.8	45
40	Usefulness of extracorporeal membrane oxygenation as a bridge to lung transplantation: A descriptive study. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 103-107.	0.6	115
41	Innate and adaptive immune responses in obliterative airway disease in rat tracheal allografts. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 707-716.	0.6	13
42	Donor Simvastatin Treatment Abolishes Rat Cardiac Allograft Ischemia/Reperfusion Injury and Chronic Rejection Through Microvascular Protection. <i>Circulation</i> , 2011, 124, 1138-1150.	1.6	69
43	Targeting Lymphatic Vessel Activation and CCL21 Production by Vascular Endothelial Growth Factor Receptor-3 Inhibition Has Novel Immunomodulatory and Antiarteriosclerotic Effects in Cardiac Allografts. <i>Circulation</i> , 2010, 121, 1413-1422.	1.6	131
44	Vascular Endothelial Growth Factor-B Acts as a Coronary Growth Factor in Transgenic Rats Without Inducing Angiogenesis, Vascular Leak, or Inflammation. <i>Circulation</i> , 2010, 122, 1725-1733.	1.6	129
45	310: Direct Microvascular Endothelial Stabilization by Donor Simvastatin Treatment Prevents Endothelial-to-Mesenchymal Transition and Vasculopathy of Cardiac Allografts. <i>Journal of Heart and Lung Transplantation</i> , 2010, 29, S105-S105.	0.6	0
46	418: Extracorporeal Membrane Oxygenation as a Bridge to Lung Transplantation in Severe End Stage Pulmonary Disease. <i>Journal of Heart and Lung Transplantation</i> , 2010, 29, S138-S138.	0.6	0
47	Natural course and risk factors for impaired renal function during the first year after heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2010, 29, 633-640.	0.6	35
48	Increased Th17 rather than Th1 alloimmune response is associated with cardiac allograft vasculopathy after hypothermic preservation in the rat. <i>Journal of Heart and Lung Transplantation</i> , 2010, 29, 1047-1057.	0.6	29
49	Cardiomyocyte-targeted HIF-1 α gene therapy inhibits cardiomyocyte apoptosis and cardiac allograft vasculopathy in the rat. <i>Journal of Heart and Lung Transplantation</i> , 2010, 29, 1058-1066.	0.6	13
50	Association between gastrointestinal symptoms and health-related quality of life after heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2010, 29, 1388-1394.	0.6	14
51	Control of Early Aspergillus Mortality After Lung Transplantation: Outcome and Risk Factors. <i>Transplantation Proceedings</i> , 2010, 42, 4459-4464.	0.6	21
52	PDGF-A, -C, and -D but not PDGF-B Increase TGF- β 1 and Chronic Rejection in Rat Cardiac Allografts. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 691-698.	2.4	43
53	29: Role of Vascular Endothelial Growth Factor-C in Experimental Obliterative Airway Disease. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, S70.	0.6	0
54	232: Simvastatin Treatment Inhibits the Development of Obliterative Airway Disease in Rat Tracheal Allografts. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, S144.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Tacrolimus Treatment Effectively Inhibits Progression of Obliterative Airway Disease Even at Later Stages of Disease Development. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 856-864.	0.6	19
56	Vascular endothelial growth factor in chronic rat allograft nephropathy. <i>Transplant Immunology</i> , 2008, 19, 136-144.	1.2	21
57	VEGFR-1 and -2 Regulate Inflammation, Myocardial Angiogenesis, and Arteriosclerosis in Chronically Rejecting Cardiac Allografts. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 819-825.	2.4	22
58	232: Donor treatment with simvastatin abolishes ischemia-reperfusion injury in rat cardiac allografts. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, S143.	0.6	0
59	426: Vascular endothelial growth factor-C enhances experimental obliterative bronchiolitis by inducing lymphangiogenesis. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, S213-S214.	0.6	0
60	444: Persistent PDGF-A, -C, -D transgene expression enhances cardiac allograft vasculopathy and fibrosis, but PDGF-B induces myocardial angiogenesis. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, S220.	0.6	0
61	132. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, S89-S90.	0.6	0
62	334. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, S159.	0.6	0
63	335. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, S159.	0.6	0
64	Inhibition of Tumor Necrosis Factor- α Attenuates Myocardial Remodeling in Rat Cardiac Allografts. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, 569-578.	0.6	6
65	The Effect of Platelet-Derived Growth Factor Ligands in Rat Cardiac Allograft Vasculopathy and Fibrosis. <i>Transplantation Proceedings</i> , 2006, 38, 3271-3273.	0.6	14
66	Effect of Graft Preservation and Acute Rejection on Hypoxia-Inducible Factor-1 in Rat Cardiac Allografts. <i>Transplantation Proceedings</i> , 2006, 38, 3372-3373.	0.6	3
67	Vascular Endothelial Growth Factor Plays a Major Role in Development of Experimental Obliterative Bronchiolitis. <i>Transplantation Proceedings</i> , 2006, 38, 3266-3267.	0.6	7
68	Angiogenic Growth Factors in Cardiac Allograft Rejection. <i>Transplantation</i> , 2006, 82, S22-S24.	1.0	3
69	Role of Platelet-derived Growth Factor and Vascular Endothelial Growth Factor in Obliterative Airway Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 1145-1152.	5.6	29
70	Common Protective and Diverse Smooth Muscle Cell Effects of AAV-Mediated Angiopoietin-1 and -2 Expression in Rat Cardiac Allograft Vasculopathy. <i>Circulation Research</i> , 2006, 98, 1373-1380.	4.5	37
71	Combined Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor Inhibition in Rat Cardiac Allografts: Beneficial Effects on Inflammation and Smooth Muscle Cell Proliferation. <i>Transplantation</i> , 2005, 79, 182-189.	1.0	34
72	A prospective study comparing cytomegalovirus antigenemia, DNAemia and RNAemia tests in guiding pre-emptive therapy in thoracic organ transplant recipients. <i>Transplant International</i> , 2005, 18, 1318-1327.	1.6	6

#	ARTICLE	IF	CITATIONS
73	Dual Role of Vascular Endothelial Growth Factor in Experimental Obliterative Bronchiolitis. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 1421-1429.	5.6	40
74	Role of Endogenous Endothelin-1 in Transplant Obliterative Airway Disease in the Rat. American Journal of Transplantation, 2004, 4, 713-720.	4.7	18
75	Role of angiogenic growth factors in transplant coronary artery disease. Annals of Medicine, 2004, 36, 184-193.	3.8	12
76	Platelet-derived growth factor regulates cytomegalovirus infection-enhanced obliterative bronchiolitis in rat tracheal allografts. Transplantation, 2004, 77, 655-658.	1.0	8
77	Angiotensin-1 Protects Against the Development of Cardiac Allograft Arteriosclerosis. Circulation, 2003, 107, 1308-1314.	1.6	99
78	Platelet-derived growth factor receptor inhibition reduces allograft arteriosclerosis of heart and aorta in cholesterol-fed rabbits. Transplantation, 2003, 75, 334-339.	1.0	20
79	Vascular Endothelial Growth Factor Enhances Cardiac Allograft Arteriosclerosis. Circulation, 2002, 105, 2524-2530.	1.6	119
80	Blockade of CD28/B7-2 Costimulation Inhibits Experimental Obliterative Bronchiolitis in Rat Tracheal Allografts. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 724-729.	5.6	42
81	Crosstalk of endothelin-1 and platelet-derived growth factor in cardiac allograft arteriosclerosis. Journal of the American College of Cardiology, 2002, 39, 710-717.	2.8	11
82	PDGF receptor inhibition prevents cardiac allograft arteriosclerosis in cholesterol-fed rabbits. Transplantation Proceedings, 2001, 33, 318.	0.6	5
83	Cytomegalovirus infection-enhanced chronic rejection in the rat is prevented by antiviral prophylaxis. Transplantation Proceedings, 2001, 33, 1801.	0.6	8
84	Cytological monitoring of peripheral blood, bronchoalveolar lavage fluid, and transbronchial biopsy specimens during acute rejection and cytomegalovirus infection in lung and heart-lung allograft recipients. Clinical Transplantation, 2001, 15, 77-88.	1.6	33
85	Differential regulation of somatostatin receptor types 1 and 5 in rat aorta after angioplasty. FASEB Journal, 1999, 13, 387-394.	0.5	43
86	Prevention of Cardiac Allograft Arteriosclerosis by Protein Tyrosine Kinase Inhibitor Selective for Platelet-Derived Growth Factor Receptor. Circulation, 1999, 99, 2295-2301.	1.6	63
87	Selective tyrosine kinase inhibitor for the platelet-derived growth factor receptor in vitro inhibits smooth muscle cell proliferation after reinjury of arterial intima in vivo. Cardiovascular Drugs and Therapy, 1999, 13, 159-168.	2.6	67
88	Enhanced Intimal Proliferation upon Injury to Pre-Existing Neointima and Resistance of Neointimal Cells to Cell Death. Cardiovascular Pathology, 1999, 8, 339-347.	1.6	9
89	Prevention of cardiac allograft arteriosclerosis by protein-tyrosine kinase inhibitor selective for platelet-derived growth factor receptor. Transplantation Proceedings, 1999, 31, 102.	0.6	6
90	Detailed analysis of cell profiles in peripheral blood, bronchoalveolar lavage fluid, and transbronchial biopsy specimens during acute rejection and cmv infection in lung and heart-lung allograft recipients. Transplantation Proceedings, 1999, 31, 163-164.	0.6	8

#	ARTICLE	IF	CITATIONS
91	Inhibition of obliterative bronchiolitis by platelet-derived growth factor receptor protein-tyrosine kinase inhibitor. Transplantation Proceedings, 1999, 31, 187.	0.6	8
92	Inhibition of complement reduces obliterative bronchiolitis. Transplantation Proceedings, 1999, 31, 188.	0.6	5
93	CMV Infection and Allograft Rejection. Transplantation Proceedings, 1998, 30, 916-917.	0.6	13
94	Immunobiology and pathology of chronic rejection. Transplantation Proceedings, 1997, 29, 77-78.	0.6	15
95	Cytomegalovirus infection accelerates experimental obliterative bronchiolitis via platelet-derived growth factor upregulation. Transplantation Proceedings, 1997, 29, 798.	0.6	4
96	Expression of platelet-derived growth factor in the development of cardiac allograft vasculopathy in the rat. Transplantation Proceedings, 1997, 29, 1045-1046.	0.6	11
97	Cytomegalovirus Infection—Enhanced Cardiac Allograft Vasculopathy Is Abolished by DHPG Prophylaxis in the Rat. Circulation, 1997, 95, 2614-2616.	1.6	56
98	Cytomegalovirus infection-enhanced chronic kidney allograft rejection is linked with intercellular adhesion molecule-1 expression. Kidney International, 1996, 50, 526-537.	5.2	72
99	Cytomegalovirus infection accelerates obliterative bronchiolitis of rat tracheal allografts. , 1996, 9 Suppl 1, 221-222.		1
100	De novo expression of endothelial sialyl Lewis(a) and sialyl Lewis(x) during cardiac transplant rejection: superior capacity of a tetravalent sialyl Lewis(x) oligosaccharide in inhibiting L-selectin-dependent lymphocyte adhesion.. Journal of Experimental Medicine, 1995, 182, 1133-1141.	8.5	95
101	Cytomegalovirus Antigen Expression, Endothelial Cell Proliferation, and Intimal Thickening in Rat Cardiac Allografts After Cytomegalovirus Infection. Circulation, 1995, 92, 2594-2604.	1.6	85
102	Induction of adhesion molecules on the endothelia of rejecting cardiac allografts. Journal of Heart and Lung Transplantation, 1995, 14, 205-13.	0.6	15
103	Cytomegalovirus infection accelerates mRNA expression of several smooth muscle cell growth factors in the allograft vascular wall. Transplantation Proceedings, 1995, 27, 566-7.	0.6	7
104	Molecular mechanisms of chronic renal allograft rejection. Kidney International, Supplement, 1995, 52, S2-10.	0.1	5
105	Vascular cell adhesion molecule-1 (VCAM-1) is induced during cytomegalovirus infection in vascular structures of heart allografts. Transplant International, 1994, 7, 363-364.	1.6	8
106	Enhancement of transplantation-associated atherosclerosis by CMV, which can be prevented by antiviral therapy in the form of HPMPC. Transplant International, 1994, 7, 365-370.	1.6	33
107	Frequency of infections and their relation to episodes of acute rejection among heart allograft recipients. Presse Medicale, 1994, 23, 1252-6.	1.9	3
108	Triple-drug immunosuppression significantly reduces chronic rejection in noninfected and RCMV-infected rats. Transplantation Proceedings, 1994, 26, 1727-8.	0.6	4

#	ARTICLE	IF	CITATIONS
109	Chronic Allograft Rejection. Immunological Reviews, 1993, 134, 33-81.	6.0	240
110	Cytomegalovirus infection enhances allograft arteriosclerosis in the rat. Transplantation Proceedings, 1993, 25, 1406-7.	0.6	10
111	Towards understanding the pathophysiology of chronic rejection. The Clinical Investigator, 1992, 70, 780-90.	0.6	40